4 citations · 4 across the 2 of their papers we have counts for
2 papers
stat.AP2024
TITE-CLRM: Towards efficient time-to-event dose-escalation guidance of multi-cycle cancer therapies
Lukas Andreas Widmer, Sebastian Weber, Yunnan Xu +1
Treatment of cancer has rapidly evolved over time in quite dramatic ways, for example from chemotherapies, targeted therapies to immunotherapies and chimeric antigen receptor T-cel…
stat.AP2022★ 4 cited
The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies
Jonathan M Siegel, Hans-Jochen Weber, Stefan Englert
The ICH E9 (R1) Estimands Guidance1 terminology does not completely address the conceptual needs of time-to-event estimands in the complex oncology context. We previously described…